Non-Vitamin K antagonist oral anticoagulants (NOACs): A view from the laboratory

British Journal of Biomedical Science

Volumn 71, Issue 4, 2014, Pages 158-167

  Blann, A D ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Apixaban; Dabigatran; Edoxaban; Heparin; Heparin, low molecular weight; NOAC; Oral anticoagulation; Rivaroxaban

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; THIAZOLE DERIVATIVE; THIOPHENE DERIVATIVE; VITAMIN K GROUP;

ANTICOAGULATION; BLEEDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; MEDLINE; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; THROMBOPLASTIN TIME; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; HEMORRHAGE; ORAL DRUG ADMINISTRATION; THROMBOSIS; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMORRHAGE; HUMANS; MORPHOLINES; PYRAZOLES; PYRIDINES; PYRIDONES; THIAZOLES; THIOPHENES; THROMBOSIS; TREATMENT OUTCOME; VITAMIN K;

EID: 84925224400     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: 10.1080/09674845.2014.11669981     Document Type: Review

References (95)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362 (6423): 801-9.
2. Hennekens CH. Aspirin in the treatment and prevention of cardiovascular disease. Annu Rev Public Health 1997; 18: 37-49.
3. ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to the global disease burden. J Thromb Haemost 2014: 12 (10): 1580-90.
4. Blann AD, Lip GY. Venous thromboembolism. BMJ 2006; 332 (7535): 215-9.
5. Lip GY, Tse HF, Lane DA. Atrial fibrillation. Lancet 2012; 379 (9816): 648-61.
6. Buller HR, Sohne M, Middeldorp S. Treatment of venous thromboembolism. J Thromb Haemost 2005; 3 (8): 1554-60.
7. Turpie AG, Chin BS, Lip GY. Venous thromboembolism: pathophysiology, clinical features and prevention. BMJ 2002; 325 (7369): 887-90.
8. Blann AD, Khoo CW. The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants. Vasc Health Risk Manag 2009; 5: 693-704.
9. Gross PL, Weitz JI. New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol 2008; 28: 380-6.
10. Husted S, De Caterina R, Andreotti F et al.; ESC Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel. Thromb Haemost 2014; 111: 781-2.
11. Keeling D, Baglin T, Tait C et al.; British Committee for Standards in Haematology. Guidelines on oral anticoagulation with warfarin-4th edn. Br J Haematol 2011; 154 (3): 311-24.
12. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl): 204S-233S.
13. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64 (3): 292-303.
14. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005; 78 (4): 412-21.
15. Wong PC, Crain EJ, Xin B et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost 2008; 6 (5): 820-9.
16. Ogata K, Mendell-Harary J, Tachibana M et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010; 50 (7): 743-53.
17. Eriksson BI, Dahl OE, Rosencher N et al.; RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, non-inferiority trial. Lancet 2007; 370 (9591): 949-56.
18. Eriksson BI, Dahl OE, Rosencher N et al.; RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5 (11): 2178-85.
19. Connolly SJ, Ezekowitz MD, Yusuf S et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361 (12): 1139-51.
20. Wallentin L, Yusuf S, Ezekowitz MD et al.; RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376 (9745): 975-83.
21. Perzborn E, Strassburger J, Wilmen A et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct factor Xa inhibitor. J Thromb Haemost 2005; 3 (3): 514-21.
22. Kakkar AK, Brenner B, Dahl OE et al.; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled study. Lancet 2008; 372 (9632): 31-9.
23. Lassen MR, Ageno W, Borris LC et al.; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358 (26): 2776-86.
24. Agnelli G, Gallus A, Goldhaber SZ et al.; for the ODIXa-DVT Study Investigators. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT study. Circulation 2007; 116 (2): 180-7.
25. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365 (10): 883-91
26. Prins MH, Lensing AW, Bauersachs R et al.; EINSTEIN Investigators. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013; 11 (1): 21.
27. Botticelli Investigators, Writing Committee, Buller H, Deitchman D, Prins M, Segers A. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 2008; 6 (8): 1313-8.
28. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P; ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010; 375 (9717): 807-15.
29. Pineo GF, Gallus AS, Raskob GE et al. Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups. J Thromb Haemost 2013; 11 (3): 444-51.
30. Granger CB, Alexander JH, McMurray JJ et al.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11): 981-92.
31. Wallentin L, Lopes RD, Hanna M et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation 2013; 127 (22): 2166-76.
32. Hokusai-VTE Investigators, Büller HR, Décousus H, Grosso MA et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369 (15): 1406-15.
33. Giugliano RP, Ruff CT, Braunwald E et al.; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369 (22): 2093-104.
34. Raskob G, Cohen AT, Eriksson BI et al. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind doseresponse study. Thromb Haemost 2010; 104 (3): 642-9.
35. Heidbuchel H, Verhamme P, Alings M et al.; European Heart Rhythm Association. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15 (5): 625-51.
36. Rachidi S, Aldin ES, Greenberg C, Sachs B, Streiff M, Zeidan AM. The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery. Expert Rev Hematol 2013; 6 (6): 677-95.
37. Harenberg J, Weiss C. Clinical trials with new oral anticoagulants. Additive value of indirect comparisons also named network meta-analyses. Hamostaseologie 2013; 33 (1): 62-70.
38. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69 (3): 236-9.
39. Barnes GD, Kaatz S, Golgotiu V et al. Use of warfarin for venous thromboembolism prophylaxis following knee and hip arthroplasty: results of the Michigan Anticoagulation Quality Improvement Initiative (MAQI2). J Thromb Thrombolysis 2013; 35 (1): 10-4.
40. Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score. Chest 2013; 144 (5): 1555-63.
41. Wan Y, Heneghan C, Perera R et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 2008; 1 (2): 84-91.
42. Witt DM, Delate T, Clark NP et al. Non-adherence with INR monitoring and anticoagulant complications. Thromb Res 2013; 132 (2): e124-30.
43. Lip GY, Haguenoer K, Saint-Etienne C, Fauchier L. Relationship of the SAME-TT2R2 score to poor quality anticoagulation, stroke, clinically relevant bleeding and mortality in patients with atrial fibrillation. Chest 2014; 146 (3): 719-26.
44. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihaemostatic medicinal products in nonsurgical patients. J Thromb Haemost 2005; 3 (4): 692-4.
45. Schulman S, Beyth RJ, Kearon C, Levine MN; American College of Chest Physicians. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edn). Chest 2008; 133 (6 Suppl): 257S-298S.
46. Baglin T. Clinical use of new oral anticoagulant drugs: dabigatran and rivaroxaban. Br J Haematol 2013: 163 (2); 160-7.
47. Keeling D, Baglin T, Tait C et al.; British Committee for Standards in Haematology. Guidelines on oral anticoagulation with warfarin-4th edn. Br J Haematol 2011; 154 (3): 311-24.
48. Kearon C, Akl EA, Comerota AJ et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis (9th edn): American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e419S-94S.
49. Fawole A, Daw HA, Crowther MA. Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban. Cleve Clin J Med 2013; 80 (7): 443-51.
50. Holster IL, Hunfield NG, Kuipers EJ, Kruip MJ, Tjwa ET. On the treatment of new oral anticoagulant-associated gastrointestinal hemorrhage. J Gastrointestin Liver Dis 2013: 22 (2); 229-31.
51. Majeed A, Schulman S. Bleeding and antidotes in new oral anticoagulants. Best Pract Res Clin Haematol 2013; 26 (2): 191-202.
52. Schulman S. New oral anticoagulant agents-general features and outcomes in subsets of patients. Thromb Haemost 2014; 111 (4): 575-82.
53. Steiner T, Bohm M, Dichgans M et al. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs) apixaban, dabigatran and rivaroxaban. Clin Res Cardiol 2013; 102 (6): 399-412.
54. Dinkelaar J, Patiwael S, Harenberg J, Leyte A, Brinkman HJ. Global coagulation tests: their applicability for measuring direct factor Xa-and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate. Clin Chem Lab Med 2014; 52 (11): 1615-23.
55. Rohde G. Determination of rivaroxaban - a novel, oral, direct factor Xa inhibitor-in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 872 (1-2): 43-50.
56. Clemens A, van Ryn J, Sennewald R et al. Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile. Eur J Clin Pharmacol 2012; 68 (5): 607-16.
57. Antovic JP, Skeppholm M, Eintrei J et al. Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. Eur J Clin Pharmacol 2013; 69 (11): 1875-81.
58. Douxfils J, Dogné JM, Mullier F et al. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb Haemost 2013; 110 (3): 543-9.
59. Baglin T, Keeling D, Kitchen S. Effects on routine coagulation screens and assessment of anticoagulation intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Society for Standards in Haematology. Br J Haematol 2012; 159 (4): 427-9.
60. Samama MM, Guinet C. Laboratory assessment of new anticoagulants. Clin Chem Lab Med 2011: 49 (5): 761-72.
61. Lindahl TL, Baghaei F, Blixter IF et al.; Expert Group on Coagulation of the External Quality Assurance in Laboratory Medicine in Sweden. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011; 105 (2): 371-8.
62. van Ryn J, Stangier J, Haertter S et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103 (6): 1116-27.
63. Chin PK, Patterson DM, Zhang M et al. Coagulation assays and plasma fibrinogen concentrations in real-world patients with atrial fibrillation treated with dabigatran. Br J Clin Pharmacol 2014; 78 (3): 630-8. doi: 10.1111/bcp.12366.
64. Hapgood G, Butler J, Malan E, Chunilal S, Tran H. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples. Thromb Haemost 2013; 110 (2): 308-15.
65. Huisman MV, Lip GY, Diener HC, Brueckmann M, van Ryn J, Clemens A. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012; 107 (5): 838-47.
66. Hillarp A, Baghaei F, Fagerberg Blixter I et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011; 9 (1): 133-9.
67. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012; 23 (2): 138-43.
68. Samama MM, Martinoli JL, LeFlem L et al. Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost 2010; 103 (4): 815-25.
69. Arachchillage DR, Efthymiou M, Lawrie AS, Machin SJ, Mackie IJ, Cohen H. Comparative sensitivity of commonly used thromboplastin to ex vivo therapeutic rivaroxaban levels. Thromb Haemost 2014; 112 (2): 421-3.
70. Douxfils J, Mullier F, Loosen C, Chatelain C, Chatelain B, Dogné JM. Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res 2012; 130 (6): 956-66.
71. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005; 61 (12): 873-80.
72. Samama MM, Contant G, Spiro TE et al.; Rivaroxaban Anti-Factor Xa Chromogenic Assay Field Trial Laboratories. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012; 107 (2): 379-87.
73. Altman R, Gonzalez CD. Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs. Thromb J 2014; 12 (1): 7.
74. Hillarp A. Gustafsson KM, Faxalv L et al. Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-Xa assays. J Thromb Haemost 2014; 12 (9): 1545-53.
75. Frost C, Nepal S, Wang J et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol 2013; 76 (5): 776-86.
76. Lippi G, Ardissino D, Quintavalla R, Cervellin G. Urgent monitoring of direct oral anticoagulants in patients with atrial fibrillation: a tentative approach based on routine laboratory tests. J Thromb Thrombolysis 2014; 38 (2): 269-74.
77. Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010; 104 (6): 1263-71.
78. Gouin-Thibault I, Flaujac C, Delavenne X et al. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study. Thromb Haemost 2014; 111 (2): 240-8.
79. Barrett YC, Wang Z, Knabb RM. A novel prothrombin time assay for assessing the anticoagulant activity of oral factor Xa inhibitors. Clin Appl Thromb Hemost 2013; 19 (5): 522-8.
80. Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant activity of the target-specific oral anticoagulant drugs. J Am Coll Cardiol 2014; 64 (11): 1128-39.
81. Martinuzzo ME, Barrera LH, D'adamo MA, Otaso JC, Gimenez MI, Oyhamburu J. Frequent false-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin. Int J Lab Hematol 2014; 36 (2): 144-50.
82. Cushman M, Lim W, Zakai NA. Clinical practice guide on antithrombotic drug dosing and management of antithrombotic drug-associated bleeding complications in adults. February 2014 Edition (www.hematology.org/Clinicians/ Guidelines-Quality/Quick-Ref/2869.aspx).
83. Alikhan R, Rayment R, Keeling D et al. The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran. Emerg Med J 2014; 31 (2): 163-8.
84. Siegal DM, Crowther MA. Acute management of bleeding in patients on novel oral anticoagulants. Eur Heart J 2013; 34 (7): 489-500.
85. Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W. Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the ISTH. J Thromb Haemost 2013; 11: 756-60.
86. Kitchen S, Gray E, Mackie I, Baglin T, Makris M. Measurement of non-coumarin anticoagulants and their effects on tests of haemostasis: Guidance from the British Committee for Standards in Haematology. Br J Haematol 2014; 166 (6): 830-41.
87. Blann AD, Lip GY. Laboratory monitoring of the non-vitamin K oral anticoagulants (NOACs). J Am Coll Cardiol 2014; 64 (11): 1140-2.
88. Ganetsky VS, Hadley DE, Thomas TF. Role of novel and emerging oral anticoagulants for secondary prevention of acute coronary syndromes. Pharmacotherapy 2014; 34 (6): 590-604.
89. Ahrens I, Peter K, Lip GY, Bode C. Development and clinical applications of novel oral anticoagulants. Part II. Drugs under clinical investigation. Discov Med 2012; 13 (73): 445-50.
90. Ellis DJ, Usman MH, Milner PG, Canafax DM, Ezekowitz MD. The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation. Circulation 2009; 120 (12): 1029-35.
91. Eikelboom JW, Connolly SJ, Brueckmann M et al.; RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013; 369 (13): 1206-14.
92. van der Hulle T, den Exter PL, Kooiman J, van der Hoeven JJ, Huisman MV, Klok FA. Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism. J Thromb Haemost 2014; 12 (7): 1116-20.
93. Gerotziafas GT, Mahe I, Elalamy I. New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients. Ther Clin Risk Manag 2014; 10: 423-36.
94. Di Nisio M, Carrier M, Lyman GH, Khorana AA. Prevention of venous thromboembolism in hospitalized medical cancer patients: guidance from the SSC of the ISTH. J Thromb Haemost 2014; 12 (10): 1746-9.
95. Wood S, Petty D, Fay M, Lewington A. Assessing kidney function in oral anticoagulant prescribing: an aid for safer drug and dose choices. Br J Cardiol 2013; 20 (2): 61-4.